MISOPROSTOL REGISTRATION COMPLETED
Addis Ababa, June 2010
DKT/E finalized registration for Misoprostol, a prostaglandin-based drug used to treat post-partum haemorrhaging (PPH), this June 2010.
Every year, thousands of women die in Ethiopia from bleeding resulting from delivery (PPH); Misoprostol is expected to significantly reduce this problem by equipping health care providers with a means to stop vaginal bleeding following delivery.
"This is an important development for our country and organization," says Negussie G/Tsadik, DKT/E's Senior Executive.
It's a tragedy that thousands of women die every year simply by giving birth. Misoprostol will help deal with this problem."
PPH is one of the leading causes of maternal mortality in Ethiopia. Women experiencing PPH often die in their homes shortly after giving birth; those that are able to make it to health care facilities often die in the hands of providers who do not have the medicines or training required to stop the bleeding.
